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Identifying protective 
Streptococcus pyogenes vaccine 
antigens recognized by both B and 
T cells in human adults and children
Rasmus Mortensen1,2, Thomas Nørrelykke Nissen3, Sine Fredslund1, 
Ida Rosenkrands1,  Jan Pravsgaard Christensen2, Peter Andersen1 & Jes Dietrich1
No commercial vaccine exists against Group A streptococci (GAS; Streptococcus pyogenes) and only 
little is known about anti-GAS protective immunity. In our effort to discover new protective vaccine 
candidates, we selected 21 antigens based on an in silico evaluation. These were all well-conserved 
among different GAS strains, upregulated in host-pathogen interaction studies, and predicted to be 
extracellular or associated with the surface of the bacteria. The antigens were tested for both antibody 
recognition and T cell responses in human adults and children. The antigenicity of a selected group 
of antigens was further validated using a high-density peptide array technology that also identified 
the linear epitopes. Based on immunological recognition, four targets were selected and tested for 
protective capabilities in an experimental GAS infection model in mice. Shown for the first time, three of 
these targets (spy0469, spy1228 and spy1801) conferred significant protection whereas one (spy1643) 
did not.
Group A streptococci (GAS; Streptococcus pyogenes) are major human pathogens causing a wide variety of dis-
eases ranging from uncomplicated infections like pharyngitis and impetigo to life-threatening invasive diseases1. 
A conservative estimate propose that GAS infections and their sequelae account for more than 500,000 annual 
deaths2. There are no licensed vaccines against GAS.
The most studied antigen is the surface M protein where both the variable N-terminal and its conserved 
C-terminal region have been proposed as vaccine candidates3–6. However, the presence of more than 220 different 
emm types7 and the extensive amount of evidence that immune responses against the M protein are associated 
with development of post-strep sequelae8,9 have made the investigation of conserved non-M protein antigens 
attractive. Some protective non-M protein antigens, such as the streptococcal C5a peptidase (ScpA), the IL-8 
serine protease (SpyCEP) and fibronectin-binding proteins have been identified, although they have yet to enter 
clinical trials (reviewed in10,11).
The goal for this study was to identify new protective non-M protein vaccine candidates. The first selection 
criterion in our strategy was that the antigens should be upregulated following interaction with the host. The next 
requirement was an immunological recognition in human adults and children. Based on recent data, we decided 
that our vaccine candidates should be recognized by both antibodies and T cells. It is already well-established 
that antibodies have protective capacity12–17 but cellular responses have also been suggested to possess 
antibody-independent protective capacity in a murine GAS infection model18–20. In addition, in a recent study 
we showed that the majority of both children and adults not only possess antibody responses, but also strong Th1 
responses against GAS antigens21. Besides immunological recognition, we also added the criteria that antigens 
should be conserved among GAS stains and be extracellular or associated with the surface of the bacteria.
Although our strategy in part overlaps with approaches used in previous GAS antigen discovery studies22–27, 
we succeeded in identifying three undescribed GAS antigens that were all recognized by T- and B cells. We show 
that the three antigens were able to protect against infection with GAS in a murine infection model.
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Results
Selecting GAS antigens. The aim of this study was to identify and characterize protective GAS antigens 
that constitute both T- and B cell targets. Our approach was to select antigens that displayed increased gene 
expression during interaction with the host, as these are likely to represent key factors in the establishment of 
an infection. Several transcriptome studies of GAS bacteria recovered after interacting with the host have been 
published. These include experimental pharyngitis in cynomolgus macaques28, growth in human blood29, soft 
tissue infection in mice30 and phagocytosis by human polymorphonuclear leukocytes31. Among the upregulated 
genes in these studies we selected a subset that were all i) conserved with over 90% identity in most of the 26 
(gap-free) GAS genome sequences that were available at the time of the study (representing 16 emm types, see 
Supplementary table 1) and ii) predicted to have an extracellular location with the pSORT v3.0 online software 
or to be integral to the membrane with extracellular domains using the TMpred server32. In total, we selected 21 
GAS antigens (table 1) and all of these were expressed as recombinant proteins. An overview of the individual 
design for each recombinant antigen can be found in Supplementary table 2.
Antigens recognized by human IgG. All antigens were next tested for recognition by antibodies and 
T cells in humans, starting with recognition by IgG in human plasma. We first performed an initial screen for 
IgG reactivity in three pools of human plasma from 32 healthy adults (10–12 adults in each pool). This provided 
an indication of the “immune reactive” antigens, from which antigens would be selected for a more detailed 
analysis in individual donors. Spy0269, spy0469, spy1228, spy1643, spy1801 and spy2010 showed the highest IgG 
responses (Fig. 1, and Supplementary figure 1 that shows the plasma titration curves used to calculate the EC50 
values). Spy2010 (C5a peptidase; ScpA) and spy0269 are well-known protective vaccine antigens23,33, but the 
other antigens were undescribed as protective antigens in the literature, and were therefore selected for further 






locationb Biological functionc References Arrayd
spy0269 26/26 (> 98%) Cell wall prgA; Putative surface exclusion protein




spy0336 25/26 (> 99%) Membrane CsrS/CovS; two-component sensor histidine kinase
Levin  et al., Mol. 
Micro. 30 (1),  
209-219, 1998
i, ii, iii
spy0453 25/26 (> 99%) Non-cytoplasmic MtsA; metal ABC transporter substrate binding Lipoprot
Janulczyk  et al.,  
Mol. Micro. 34(3),  
596-606
ii
spy0458 25/26 (> 98%) Membrane FtsK; DNA translocase i, iv
spy0469 26/26 (> 94%) Non-cytoplasmic Putative 42 kDa protein, surface antigen ii, iv
spy0545 21/26 (> 97%) Membrane Chromosome segregation ATPase iv
spy0575 26/26 (> 99%) Membrane Putative membrane spanning protein i
spy1034 25/26 (> 91%) Membrane Putative membrane associated protein i, iv
spy1228 25/26 (> 99%) Non-cytoplasmic Putative lipoprotein, nucleoside-binding protein i, ii
spy1326 25/26 (> 98%) Membrane Uncharacterized outer surface protein
Margarit et al., 
FASEB J. 23, 
3100–3112 (2009).
iv
spy1546 22/26 (> 91%) Membrane Uncharacterized acetyltransferase i, iv
spy1592 26/26 (> 98%) Non-cytoplasmic Putative ABC transporter substrate binding Lipoprot. ii
spy1643 26/26 (> 97%) Membrane Uncharacterized protein i
spy1801 25/26 (> 92%) Cell wall isp; immunogenic secreted protein




spy1978 26/26 (> 96%) Membrane Lrp; Leucine rich protein i, ii
spy2010 24/26 (> 95%) Cell wall ScpA; steptococcal c5a peptidase
O’Conner et al., 
Infect Immun, 53(2), 
432-434, 2086
i, ii
spy2037 24/26 (> 99%) Membrane PrsA2; Foldase protein i, iii
spy2039 26/26 (> 97%) Secreted SpeB; Streptococcal cysteine proteinase Elliott, S., J Exp Med. 81(6): 573 -592, 1945 i, iii
spy2154 26/26 (> 98%) Membrane Uncharacterized protein i, ii, iv
spy2176 26/26 (> 92%) Membrane Uncharacterized protein iii, iv
spy2197 25/26 (> 97%) Membrane Putative membrane associated protein ii, iv
Table 1.  Overview of selected Streptococcus pyogenes antigens. aChecked in 26 different GAS strains with 
a local BLAST search. bpSORT software v3.0 and Tmpred server. cInferred from UniProt.org. dArray (i): 
Cynomolgus macaques [28], (ii): Blood [29], (iii): Soft tissue [30], (iv): PMN [31].
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For the analysis of individual plasma samples, we included a recombinant tuberculosis antigen (ESAT-6) as 
a negative control, which was purified in the same way as all the other antigens. Responses for each donor were 
“baseline-corrected” for every antigen by subtracting the EC50 value of the control antigen from the EC50 value 
of the GAS antigens. We defined all donors that showed responses above the baseline for a specific antigen as 
“responders” (for that particular antigen). The results showed that the antigens with the highest response in the 
pooled samples, spy0269 and spy0469, also had the highest responder frequencies in individual donors. Thus, 
all donors showed high IgG responses against these antigens (Fig. 2A and Table 2). Although not at 100%, the 
responder frequencies of spy1228, spy1643 and spy1801 were also high (88%, 94% and 78%, respectively), con-
firming the immunogenicity of these antigens. For comparison, we also measured the antibody responses in 30 
children from 5–15 years of age, and no difference in the recognition pattern was observed although the response 
frequency was slightly lower for some of the antigens (Fig. 2B and Table 2).
Figure 1. Initial screening of antigen specific IgG in human plasma pools. Total IgG specific for each of 
the 21 antigens was measured by ELISA in three plasma pools (10–12 donors in each pool). Bars represent 
geometric means of the EC50 calculated by a sigmoidal fitting of data points from a 10-fold plasma dilution 
series. Responses under 1 or too low for accurate fitting were adjusted to EC50 = 1. Grey bars indicate the 
antigens that were selected for IgG responder frequency analysis in individual donors.
Figure 2. IgG responder analysis of selected antigens. Total IgG specific for selected antigens was measured 
by ELISA in plasma from (A) adults (n = 32) and (B) school aged children from 5–15 years (n = 30). Lines 
represent medians of the EC50 calculated by a sigmoidal fitting of data points from a 10-fold plasma dilution 
series. Responses too low for accurate fitting were adjusted to EC50 = 1. Responses for spy1801 have been 
reported for this donor panel in another publication21, but plasma samples have been re-run for this antigen 
along with the other antigens in this study for direct comparison.
www.nature.com/scientificreports/
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In summary, we identified five antigens that are frequently targeted by human IgG responses in adults and 
children by performing a pre-screen of 21 conserved antigens with pooled plasma samples, followed by analysis 
of selected antigens in individual donors.
Antibody target validation and comparison with other GAS antigens. Measuring antibody 
responses against recombinant proteins expressed in E. coli involves the risk of measuring artifact responses 
against remaining contaminants from the purification process. Therefore, considering that most proteins contain 
both conformational and linear epitopes, the use of peptides to analyze antibody recognition (and avoid the 
problem with E. coli residuals) could validate that the antigens identified above were indeed targets for B cells in 
humans. As part of a separate ongoing antigen discovery project, we had access to peptide recognition data of 
all the targets selected above. These were measured by a recently developed high density peptide array technique 
where an array was synthesized spanning the entire length of all potential GAS proteins in the genome of the 
M1 SF370 strain with 15-mers overlapping with 14 amino acids (1aa spacing). This yielded a total of ~503,000 
individual peptide fields from the 1,696 different protein sequences in the genome. The array was incubated 
with a pool of plasma from six human adults from the donor panel and after staining with a Cy3-conjugated 
goat anti-human detection antibody, linear peptides binding human IgG could be detected for each protein. 
Spy0269, spy0469, spy1228, spy1643 and spy1801 were all recognized in this assay (showing one or more peaks 
above 200–300 AU, which is 25–40% of highest possible readout), although spy1228 only showed one singular 
peak above 300 AU (Fig. 3). As expected, most regions in the antigens did not bind IgG. Setting a cutoff at 25% 
of the maximum readout, we defined the most immunogenic regions (“linear B cell epitopes”) for each protein 
(Supplementary table 3). In total we found 18 stretches of immunogenic amino acids in the five proteins with 
lengths from 15 amino acids up to as much as 32 amino acids (aa185–216 in spy0269). Except for spy0545 that is 
shown as a negative control, all the proteins had at least one linear B cell epitope.
A data comparison furthermore showed that spy0269, spy0469, spy1643 and spy1801 all belonged to the 20% 
predicted proteins in the GAS genome (349 in total) with at least one epitope with a signal strength > 300AU (sin-
gular peaks omitted, data not shown). These 20% also included proteins with known protective capacity and for 
comparison a selection of these are shown in Supplementary figure 2 (showing several non-M proteins, as well as 
the M protein itself that displayed strong recognition in both the conserved and the variable region).
In summary, using a peptide array technology the five targets selected above were validated as being B cell 
targets in humans and spy0269, spy0469, spy1643 and spy1801 were furthermore found to belong to the 20% of 
the predicted GAS proteins that had at least one strong linear B cell epitope in this assay.
Antigens recognized by cellular responses in humans. Having screened the selected proteins for 
antibody responses, we next focused on the recognition by T cells. T cells might contribute to immunity by 
amplifying secondary antibody responses34 and potentially also by eliciting antibody-independent protection18–20. 
We therefore tested all the antigens for antigen-specific cellular recognition in humans. We first performed a 
pre-screen of all antigens in a small set of donors, in order to identify the most immunogenic antigens for further 
analysis (in more donors). In this initial experiment we screened 18 adult donors for IFNγ release from PBMCs 
stimulated with the 21 different antigens. We chose IFNγ as we have recently shown this cytokine to be a sensitive 
indicator of cellular immunity in GAS exposed individuals21. Thus, most donors displayed cellular secretion of 
multiple cytokines, but IFNγ responses were by far the strongest, making this marker appropriate for cellular 
screening in this study.
The results showed that the cellular immune response against GAS is distributed on multiple different anti-
gens (Fig. 4A). Spy0469, spy1228, spy1546, and spy1643 showed both a high responder frequency as well as high 
median responses. However, cellular recognition was even more pronounced for spy1801 and spy2010. In con-
trast, Spy0575 and several other antigens showed low cellular recognition (Fig. 4A).
In the next analysis we included more adults as well as school-aged children from 5–15 years. We focused our 
analysis on five cellular targets identified in the pre-screen (spy0469, spy1228, spy1546, spy1643 and spy1801). 
Spy0575 was included as a negative control. A comparison of the IFNγ responses between adults and children 
showed that the responder frequency was similar for most of the antigens, although more adults responded to 
spy0469 and spy1228 compared to children (21% vs. 55% for spy0469 (p = 0.0198, Chi-square test) and 11% vs. 
29% for spy1228 (p = 0.0809)), (Fig. 4B,C). Responder frequencies as well as the median responses for the adults 












spy0269 32/32 (100%) 3,55 29/30 (97%) 3,23
spy0469 32/32 (100%) 3,28 29/30 (97%) 3,37
spy1228 25/32 (78%) 1,66 21/30 (70%) 1,76
spy1643 28/32 (88%) 1,73 25/30 (83%) 1,84
spy1801 30/32 (94%) 1,82 21/30 (70%) 1,56
Table 2.  IgG responder frequencies of selected antibody targets measured by ELISA in both adults and 
children from 5–15 years.
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frequencies ranged from 29% for spy1228 to 65% for spy1801 in adults and 11% to 64% in children. The total 
responder frequency on any antigen was 31/32 (97%) for the adults and 27/28 (96%) for the children.
Altogether, we evaluated 21 antigens for their cellular responses in humans measured by IFNγ and identified 
five highly immunogenic antigens with responder frequencies between 29–65% in adults and 11–64% in children.
Protective efficacy of selected antigens. Based on an overall assessment of the immune recognition 
data, we chose to evaluate the protective efficacy of spy0469, spy1228, spy1643 and spy1801 in a murine skin 
infection model. We chose this model, as we find it to be a particular robust model to screen antigens for their 
protective efficacy due to low variation and stable CFU levels, in particularly between day 4 and 7 post infection. 
As shown above, all the antigens were targets for both antibody- and cellular recognition in humans and so we 
first confirmed that the antigens were also immunogenic in mice. Mice were immunized s.c. with the antigens 
three times at two-week intervals. Two weeks after the final immunization, sera from individual mice were ana-
lyzed for IgG responses against the vaccine antigen. In addition, PBMCs were obtained from blood and stimu-
lated in vitro with vaccine antigen for 72 hours, whereafter IFNγ was measured in the supernatants by ELISA. 
The results showed that all antigens were immunogenic and recognized by both cellular responses and antibodies 
(Fig. 5A,B). Furthermore, infected mice also developed IgG responses against all the selected antigens. Consistent 
with our observations in humans, the strongest responses were observed for spy0469 (Fig. 5C).
After confirming immunogenicity of the vaccine antigens in mice, immunized animals were infected by the 
intradermal (i.d.) route 6 weeks after the final immunization. Four days post infection skin biopsies from the 
infected area were analyzed for bacterial numbers. We chose day 4 because the infection in our mouse model 
peaks at day 4, whereafter it is gradually eliminated (data not shown). The results showed that spy0469, spy1228 
and spy1801 all induced significant protection compared to non-vaccinated control mice (Fig. 5D–G). The pro-
tection (reduction in bacterial burden) varied slightly between the antigens with spy1228 inducing the highest 
level of protection, similar to the positive control which was heat inactivated GAS bacteria of a homologous strain 
(HGAS; Fig. 5H). In contrast, despite being recognized by both cellular and antibody responses in immunized 
and infected mice, spy1643 did not induce protection.
In summary, we were able to identify three potentially extracellular/surface exposed, conserved and immuno-
genic antigens. All of them represented B- and T cell targets in both humans and mice, and conferred significant 
protection in a murine GAS infection model.
Analysis of cross-reactivity to human heart tissue. To address whether the identified GAS antigens 
might induce antibodies able to recognize human heart proteins, we tested murine anti-sera against each of 
the proteins for cross-reactivity to human heart extract proteins by western blots. As expected, anti-sera raised 
against the M1 and M5 protein as well as HGAS reacted with several proteins in both human heart extract as 
well as human heart valve lysate (Fig. 6A,B). In contrast, sera from spy1228 and spy0469 immunized mice did 
not react with any protein in the two different heart tissues samples, but surprisingly anti-serum against spy1801 
reacted with a protein of approx. 100 kDa. A western blot with spy1801 anti-serum from another independent 
animal experiment confirmed this observation and we moreover validated the presence of recombinant spy1801 
in the spy1801 batch used for immunization by mass spectrometry (data not shown). We also excluded that the 
cross-reactive band from spy1801 was due to E. coli contaminants in the Spy1801 batch used for immunization, 
since the spy1801 anti-serum did not react with any protein in E. coli lysates (data not shown). We thus conclude 
that, while spy0469 and spy1228 anti-serum does not react with proteins of human heart extract and heart valve 
lysate in a western blot, spy1801 anti-serum reacts with a protein of approx. 100 kDa.
Figure 3. Antibody epitopes of selected antigens identified by peptide array technology. Binding of human 
IgG to 15-mer peptides overlapping with 14 amino acids on a peptide array spanning the entire length of each 
of the selected antigens. IgG binding was measured with a Cy3-conjugated goat anti-human antibody after 
incubation with plasma pooled from six adult donors. The black bars indicate fluorescence intensity for each of 
the peptides in arbitrary units that arise from summarizing over the R, G and B channels in the resulting image 
file. Peptides were randomly distributed on the array and data was mapped back in the right sequence order of 
the antigen after the experiment.
www.nature.com/scientificreports/
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Discussion
This study describes the identification of three conserved antigens with protective capacity in an experimental 
GAS infection model. Various strategies have been employed during the last decade to identify protective non-M 
protein antigens from GAS22–26. Each of these studies identified one to nine protective antigens. Different tech-
nical approaches were adopted in these studies, which might explain why only a few antigens were identified in 
more than one study. Three such antigens were SpyCEP, ScpA and spy0269. Spy0269 was also shown in our study 
to be recognized by IgG in human plasma (Figs 1 and 2) and by our peptide array to contain several B cell epitopes 
(Fig. 3).
21 antigens passed our initial selection criteria. Six of these were recognized by cellular responses (spy0469, 
spy1228, spy1546, spy1643, spy1801 and spy2010) and six by antibodies (spy0269, spy0469, spy1228, spy1643, 
spy1801 and spy2010). Thus, there is a significant overlap between the targets of cellular and antibody responses. 
The same antigens were also recognized in infected mice suggesting that immunogenicity was independent of 
host species, and probably related to their expression and availability to the immune system. All individuals, 
except one child, exhibited adaptive immune responses to at least one GAS antigen, confirming that exposure to 
this pathogen is very common. In the i.d. infection model, immunization with spy0469, spy1228, and spy1801, 
but not spy1643, induced a significant reduction in the GAS colonization of the skin (Fig. 5D–G). This is, to our 
knowledge, the first time these antigens are described as protective antigens.
Spy1228 is a putative conserved lipoprotein35 with unknown function that has previously been shown to elicit 
an antibody response in mice and humans22. Extracellular location of this protein has also been verified experi-
mentally36. Spy0469 showed strong antibody recognition in all adults and 97% children in our study as well as cel-
lular responses in 55% of the adult donors compared to 21% of the children (p = 0.0198). The biological function 
Figure 4. Screening of antigen specific IFNγ release in human PBMCs. IFNγ measured by ELISA in 7 
day culture supernatants of stimulated PBMCs. (A) Pre-screen of the 21 different recombinant antigens in a 
smaller panel of adults (n = 18). Responder cut-off was set at 100 pg/ml. Gray marking indicate antigens with 
median responses over 500 pg/ml or over five responders. Five immunogenic antigens from this experiment 
plus a negative control were selected for further screening (marked by ‘*’). (B) Selected antigens were screened 
in an additional 13 adult donors (total n = 32) as well as (C) school aged children from 5–15 years (n = 28). 
Responses for spy1801 have been reported for this donor panel in another publication21. CMI; Cellular 
Mediated Immunity.
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of spy0469 is unknown but it contains a LysM domain that is used to locate proteins to the bacterial envelope via 
non-covalent linkage to peptidoglycan37. The extracellular location of this protein has also been verified experi-
mentally36,38. Spy1801 does not have a confirmed biological function either, but it has been suggested to play a role 
in biofilm formation as its gene is highly upregulated during biofilm formation39. Consistent with that, computa-
tional comparisons indicate that spy1801 belong to a family of peptidoglycan hydrolases that includes a member 
in Lactococcus lactis that generates peptidoglycan disruptions that are important for biofilm formation40. Spy1801 
(that is also annotated as “immunogenic secreted protein” (Isp)), is also known to induce antibody responses in 
humans41, so it was surprising that anti-sera raised against spy1801 cross-reacted with a 100 kDa protein in two 
different tissue extracts from the human heart. Although we cannot conclude that the epitope recognized by 
spy1801 anti-sera in the western blot is available for antibody recognition in vivo and thus play a potential role in 
GAS pathogenesis, it does raise a safety concern that should be further investigated.
The present work is the first to use a peptide array technology platform to identify linear B cell epitopes in 
the validation of GAS antibody targets. Using pooled serum from six donors, we confirmed the antigenicity of 
spy0269, spy0469, spy1228, spy1643 and spy1801 by identification of at least one linear antibody epitope. Subunit 
vaccines have an upper limit as to how many antigens that can be combined before recombinant expression of the 
final fusion protein become negatively affected by the molecular weight. However, numerous short linear epitopes 
like the ones identified in our study could potentially be included in a vaccine construct without obstructing 
Figure 5. Immunogenicity and protective efficacy of selected antigens in the mouse model. (A) Female 
DBA/2 mice were vaccinated three times with indicated antigens. At week 2 post vaccination, PBMCs were 
stimulated with the vaccine antigen for 72 hours and secretion of IFNγ was analyzed by ELISA. (B) The serum 
IgG against the indicated antigens was measured by indirect ELISA. Antibody titers were measured by the 
reaction of a series of 10-fold dilution of sera with the antigen. The Antibody titration from the sera of 4 mice 
are shown. Bars indicate means ± SEM. (C) The serum IgG against the indicated antigens was measured by 
indirect ELISA using pooled sera taken from eight mice two weeks after a sublethal intraperitoneal GAS 
infection. (D–G) Mice were vaccinated three times s.c. with indicated antigens. Six weeks after the final 
vaccination, mice received an intradermal infection with 107 GAS bacteria (MGAS5005). 4 days post infection 
the number of bacteria in a skin biopsy covering the entire affected area was determined. A t-test was used 
to calculate the p-value. All the antigens were tested in at least two independent experiments. For spy1228/
spy1801/spy0469 results from two such experiments are shown.
www.nature.com/scientificreports/
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recombinant expression due to size issues. This would allow the vaccine to target a large number of different 
GAS antigens. Given the high capacity of the array technology, all putative proteins in the GAS genome could be 
included in a single IgG epitope screen. By that, we were allowed to compare the signal strength of the epitopes 
from our selected targets with epitopes from every other possible protein in the M1 SF370 GAS genome. We 
found as much as 349 different proteins with at least one peak with signal strength > 300 AU (data not shown). 
These 349 proteins constituted the top 20% of the genome and included spy0469, spy1643 and spy1801 as well as 
other antigens with published protective capacity (e.g. the M1 protein3,4, Streptolysin O42 and the streptococcal 
C5a peptidase33 (Fig. 3 and supplementary figure 2). This suggests that the peptide array technology can be used 
in future screenings for protective GAS epitopes, as it is a powerful tool to identify immunogenic antigens. 
It should be noted however, that it is not fully known whether a selection strategy, based entirely on antigens/
epitopes that are recognized during an infection, is the best strategy to discover protective antigens. Indeed, in 
several cases highly recognized epitopes (both T and B cell epitopes) may not be protective43–47 and it can be 
speculated that certain key antigens/epitopes have evolved to be weakly immunogenic (“cryptic”) in order to 
evade protective immune responses against them. In line with this, the highly protective hypervariable region 
of the M protein is weakly immunogenic in infected mice and humans, but immunization with the M protein in 
a strong adjuvant that can overcome the low immunogenicity results in protective immunity13. Interestingly, we 
found that antibody responses in humans against spy1228 were substantially lower than observed for spy0469 
and spy1801. However, spy1228 showed the highest protection in immunized mice, indicating that high antibody 
titers in humans may not always be the best predictor of protective antigens, something that has also been showed 
for other infections43–47. In fact, inducing Ab response to cryptic epitopes has for viral pathogens been shown to 
result in increased protection48,49, and future Streptococcus antigen discovery strategies may consider this.
In summary, we have shown that the immune response against GAS includes both antibody and cellular 
responses against numerous different non-M protein antigens. Using immune recognition in humans as a selec-
tion criterion for evaluation in a murine skin infection model, we identified three protective non M-protein 
antigens.
Methods
Antigens. Full-length sequences of antigens upregulated in four microarray studies28–31 were obtained from 
Streptococcus pyogenes M1 SF370. Conservation of these antigens was evaluated by a BLAST search in a local 
database consisting of the 26 fully sequenced GAS genomes that were available at the time of the study (see 
Supplementary table 1). The genomes in the database were downloaded from the NCBI genome database (http://
www.ncbi.nlm.nih.gov/genome/genomes/). Based on either being predicted to have an extracellular location 
with the pSORT v3.0 online software or to be integral to the membrane with extracellular domains using the 
TMpred server32, 21 conserved antigens were selected. Sequences of the 21 antigens were codon-optimized for 
expression in Escherichia coli (E. coli). Transmembrane helices predicted by the TMpred server, were deleted 
Figure 6. Cross-reactivity towards human heart tissue proteins. Anti-serum from mice vaccinated with the 
proteins indicated in the figure was used to test for cross-reactivity towards (A) human heart extract and (B) 
human heart aorta valve lysate by western blotting. The molecular weight markers in kilo Dalton (kDa) are 
indicated.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:22030 | DOI: 10.1038/srep22030
for ease of expression and remaining fragments were linked by a sequence of -(GGGGS)2- (see Supplementary 
table 2 for detailed information on individual antigens). The sequences were made by chemical synthesis with 
an N-terminal His6-Tag followed by insertion into the commercial expression vector pJexpress 411 (DNA2.0). 
After transformation of E. coli BL21 AI (Invitrogen), protein expression was induced with 1 mM isopropyl β -D-1-
thiogalactopyranoside (IPTG) and recombinant protein was purified as previously described50. Heat inactivated 
GAS bacteria (HGAS) were made by harvesting GAS colonies from blood agar plates in Tris-HCL buffer pH 7.5 
before determining the bacterial concentration by plating. Bacteria were then diluted to 109 CFU/ml and killed 
by heating the suspension for 120 min at 60 °C. As positive controls in western blotting experiments with human 
heart tissue samples, we also used recombinant streptococcal M proteins from M1 (SF370) and M5 (Manfredo), 
which were purified in the same way as described above.
The recombinant proteins selected for protection experiments were verified by Mass spectrometry after puri-
fication (data not shown).
Human subjects. We enrolled two groups of volunteers; 32 healthy adults aged > 20 years, and 30 
school-aged children from 5–15 years as part of another recent study21. A simple questionnaire was used to 
screen the donors and all of them replied that they had not had a “sore throat” for at least 3 months before the 
blood samples were taken. The study was carried out in accordance with the regulations set forward by the Danish 
Ministry of Health and approved by the Committee on Health Research Ethics in the Capital Region (protocol no. 
H-2-2014-057) and the Danish Data Protection Agency (J. no. 2014-54-0733). Informed consent was obtained 
from all subjects.
Lymphocyte cultures. PBMCs were purified from fresh heparinized blood using a density gradient. After 
washing, cells were incubated at 37 °C in round bottom 96-well microtiter plates (Nunc) in 200 μ l serum-free 
AIM-V medium (Gibco; Invitrogen) containing 3 × 105 human cells, or 2 × 105 murine cells in 200 μ l RPMI-1640 
supplemented with 5 × 10−5 M 2-mercaptoethanol, 1 mM glutamine, 1% pyruvate, 1% penicillin-streptomycin, 
1% HEPES and 10% fetal calf serum (FCS) (Gibco; Invitrogen). Recombinant antigens were used in concentra-
tions of 5 μ g/ml and as a positive control streptococcal Enterotoxin B was used in 1 μ g/ml. Supernatants in dupli-
cates or triplicates were harvested from cultures after 3–7 days for IFNγ ELISA.
IFNγ ELISA. A sandwich ELISA was used to determine the concentration of IFNγ in culture supernatants as 
previously described for human samples21 and murine samples51.
Detection of antigen-specific antibodies by ELISA. Maxisorp micro titer plates (Nunc, Maxisorp) 
were coated with the individual recombinant antigens in a concentration of 0.5 μ g/ml and antibody levels in 
serum/plasma samples were determined by ELISA as previously described21. In brief, free binding sites were 
blocked with 3% skimmed milk (w/v) and plates were incubated with individual plasma samples in 10-fold 
serial dilutions starting with a 1:10 dilution. Antigen-specific IgG was detected with HRP-conjugated second-
ary antibodies which for human samples was polyclonal rabbit anti-human IgG (Dako) diluted 1:6000 or rab-
bit anti-mouse IgG (Zymed) diluted 1∶ 5000 for murine samples. Substrate was TMB-PLUS (Kem-En-TEC). 
Reciprocal serum dilutions corresponding to 50% maximal binding (EC50) were computed using the GraphPad 
Prism 6.04.
SDS-PAGE and Western blot analysis. 4–20% Mini-PROTEAN® TGX precast gels (Bio-Rad, Hercules, 
CA) were used, and 20 μ g of human heart extract (sc-363763 from Santa Cruz Biotechnology, Dallas, TX) or 
human heart aorta valve whole tissue lysate (NB820-59218 from Novus Biologicals, Littleton, CO) were applied 
in each lane. Proteins were transferred to nitrocellulose by the Trans-Blot® Turbo™ transfer system (BioRad), the 
nitrocellulose was blocked in PBS with 5% skimmed milk, 0.1% Tween 20 and thereafter incubated with mouse 
serum samples diluted 1:200. Antigen-specific immunoglobulins were detected with alkaline phosphatase con-
jugated secondary antibodies.
High-density peptide arrays of selected antigens. A peptide array spanning the entire length of all 
predicted proteins in the entire genome of the M1 SF370 GAS strain (1,696 predicted proteins) was synthesized 
with 15-mers overlapping with 14 amino acids (~503,000 individual peptide fields). The layout of the array was 
made with proprietary software using the FASTA sequence of GAS M1 SF370 as input. Peptides spanning human 
serum albumin, were also included on the array as a negative control protein that does not bind human IgG. All 
peptides were randomly distributed on the chip to reduce the possible effect of local area-specific noise. Arrays 
were made by Schafer-N® using maskless photolithographic synthesis adapted to solid phase peptide synthesis 
with the peptide C-terminal linked to the surface of the array. The microarray was incubated for 2 hours with a 
1:200 dilution of pooled plasma from six randomly selected human adults. After washing the arrays were stained 
for 2 hours with 1 μ g/ml of a Cy3-conjugated goat anti-human detection antibody. Images of stained arrays were 
recorded using an InnoScan900 micro array scanner (Innopsys) with an excitation wavelength of 532 nm and 
fluorescence intensity for each peptide field was calculated by summarizing over the R, G and B channels in the 
resulting image file.
Bacterial strains and growth. GAS strain MGAS5005 (serotype M1) was grown at 37 °C with 5% CO2 
in Todd-Hewitt broth (SSI Diagnostica) or on 5% blood agar (SSI Diagnostica) that was used as solid medium.
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Animal experiments. Female DBA/2 mice at 5–8 weeks of age were purchased at Harlan Laboratories 
(Horst, The Netherlands) and randomized to cages upon arrival. Handling of the animals was conducted in 
accordance with the regulations of the Danish Ministry of Justice and animal protection committees and in 
compliance with the EU Directive 2010/63/EU. The methods were carried out in accordance with the approved 
guidelines. All animal experiments were approved by an institutional animal committee. Mice were immu-
nized subcutaneously (s.c.) at the base of the tail with 5 μ g of recombinant antigen formulated in AddaVaxTM 1:1 
(Invivogen). Three immunizations were performed with a two-week interval and four weeks after last immuniza-
tion, mice received an intradermal (i.d.) injection of 0.5–1 × 107 CFU (GAS strain MGAS M5005, M1 serotype). 
The mice were sacrificed 4 days post infection and skin biopsies were obtained by excising a specimen of 1–1.5 cm 
in diameter around the infected area. Vaccine-induced protection was evaluated by counting the CFUs obtained 
from plating suitable dilutions of skin homogenates.
Statistics. CFU levels in challenged mice were compared by a student’s t-test in two independent animal 
experiments for each antigen. A chi-square test was used to compare responder frequencies in human adults and 
children. p < 0.05 was considered significant. All statistical analyses were carried out in GraphPad Prism version 
6.04 (GraphPad Software Inc.).
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